Phase 2
N=18
Biomarkers of Irritant-Induced and Allergic Asthma
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT02740543 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcome: Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Fluticasone propionate HFA 220 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NYU Langone Health
- Primary completion
- Oct 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in TSLP Gene Expression |
0.000197; 0.000035 | — |
Summary
Asthma is a heterogeneous disease, and although much is understood about mechanisms of inflammation in allergic asthma, less is known about mechanisms of irritant-induced asthma (IA). Understanding the underlying similarities and differences in mechanisms of these two types of asthma will help focus current treatments and lead to development of new therapies. There is a longstanding NYU/Bellevue Asthma registry (NYUBAR), with a large population (N = 900) of asthma cases and controls, a program that has been housed at the CTSI (formerly GCRC). The destruction of the World Trade Center (WTC) resulted in massive dust, gas and fume exposures to local residents, workers and cleanup workers and individuals involved in rescue and recovery and adverse respiratory health effects of this disaster are reported more than 7 years after 9/11. Many responders, as well as those exposed as residents or local workers, have developed IA, asthma that arises after a lag from an environmental exposure . The WTC Environmental Health Center (WTC EHC) is one of the three New York City (NYC) WTC Centers of Excellence and the only one that focuses on treatment and monitoring of local workers and residents. As such, it has a large population of individuals with irritant-induced asthma. It has been proposed to use participants from the NYUBAR and the WTC EHC to expand the knowledge of irritant and allergic asthma. Non-invasive studies allow for the assessment of airway inflammation, a non-specific response to environmental exposure and injury. Recent technologies also allow for assessment of microRNA (miRNA), small RNAs that regulate gene expression at the post-transcriptional level and thus serve as a pathway to regulation of inflammation. The hypothesis will be tested in that airway inflammation in irritant and allergic asthma may be similar, but result from divergent miRNA regulatory pathways expressed in sputum cells. These studies will provide preliminary data for future studies that will help identify biological pathways to categorize these asthma phenotypes and target future treatment interventions.
Eligibility Criteria
Inclusion Criteria
For the WTC population with Irritant-Induced Asthma (IA):
- > 18 years of age*
- Current nonsmoker*
- 2x / week) in the 4 weeks before inclusion (persistent symptoms).
Inclusion for Allergic Asthma Population (AA):
- All of the above items with an asterisk (*)
- Patients will be recruited from the NYUBAR or advertisement and will have asthma as defined by NIH guidelines, persistent symptoms, absence of WTC dust exposure.
- Participants who will have completed the Phase I of the study and were able to produce adequate sputum samples.
Inclusion of Control Population:
- Patients will be recruited from the NYUBAR and will have no respiratory symptoms, no asthma diagnosis, no WTC dust exposure, no current tobacco use, ≤ 5 p-y history of tobacco use, and normal spirometry with no bronchodilator response and negative methacholine challenge in past 6 months.
Inclusion Criteria for Phase II:
- Successfully completed Phase I
- Has asthma according to Phase I diagnostic criteria
- Signed consent to be re-contacted
Exclusion Criteria
- Current Smoker
- Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung Disease
- Cardiac Disease
- Inability to perform lung function or other maneuvers
- Upper respiratory tract infection within the last 4 weeks
- FEV1 <60% predicted normal pre-bronchodilator
- Oral corticosteroid treatment within the last 4 weeks.
- No vulnerable subjects will be part of this study.
Data sourced from ClinicalTrials.gov (NCT02740543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.